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Background: The objective of this study was to identify prognostic factors for survival in patients with primary
diffuse large B-cell lymphoma (DLBCL) of the adrenal gland.
Methods: Thirty one patients diagnosed with primary adrenal DLBCL from 14 Korean institutions and treated with
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) were analyzed.
Results: Complete remission (CR) and overall response rate after R-CHOP chemotherapy were 54.8% and 87.0%.
The 2-year estimates of overall survival (OS) and progression-free survival (PFS) were 68.3% and 51.1%. In patients
achieving CR, significant prolongations of OS (P= 0.029) and PFS (P= 0.005) were observed. Ann Arbor stage had no
influence on OS. There was no significant difference in OS between patients with unilateral involvement of adrenal
gland and those with bilateral involvement. When staging was modified to include bilateral adrenal involvement as
one extranodal site, early stage (I or II) significantly correlated with longer OS (P= 0.021) and PFS (P <0.001).
Conclusions: Contrary to prior reports, our data suggests that outcomes of primary adrenal DLBCL are encouraging
using a regimen of R-CHOP, and that achieving CR after R-CHOP is predictive of survival. Likewise, our modified
staging system may have prognostic value.
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Primary extranodal non-Hodgkin’s lymphoma (NHL) is
characterized by disease confined wholly or chiefly to an
extranodal site [1]. The adrenal gland is an extremely
rare site of primary extranodal NHL, accounting for less
than 1% of all NHL and only 3% of primary extranodal* Correspondence: hemakim@yuhs.ac
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reproduction in any medium, provided the orlymphomas [2,3]. While bilateral involvement of adrenal
gland, predominantly male and elderly, and frequent as-
sociation with adrenal insufficiency are commonly re-
ported clinical features of primary adrenal NHL, diffuse
large B-cell lymphoma (DLBCL) is the most common
histologic subtype, with a non-germinal center B-cell
(non-GCB) phenotype [4-7]. To date, only about 120
publications (case reports or patient series) appear in the
literature, each limited in scope. Conclusions have thus
been drawn from clinical data and treatment outcomes. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patients characteristics
Characteristics Number of patients Percentage
Age
≤ 60 12 38.7
> 60 19 61.3
Gender
Male 23 74.2
Female 8 25.8
ECOG PS
0-1 27 87.1
2-4 4 12.9
B symptom
Absent 14 48.3
Present 15 51.7
Bulky disease
Absent 21 67.7
Present 10 32.3
LDH
Normal 4 12.9
Elevated 27 87.1
Primary site of adrenal gland
Unilateral 12 38.7
Bilateral 19 61.3
Adrenal insufficiency
Absent 10 62.5
Present 6 37.5
Ann Arbor stage
IE, IIE 5 16.1
IIIE, IV 26 83.9
Number of extranodal sites
0-1 7 22.6
2 or more 24 77.4
Ki-67 LI
> 80% 11 57.9
≤ 80% 8 42.1
IPI
Low/Low-intermediate 8 25.8
High-intermediate/High 23 74.2
ECOG PS, Eastern Cooperative Oncology Group performance status; LDH,
lactate dehydrogenase; Ki-67 LI, Ki-67 labeling Index; IPI, International
Prognostic Index.
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nature of primary adrenal NHL.
The prognosis of primary adrenal DLBCL has hereto-
fore been considered quite poor, entailing 1-year overall
survival (OS) rate as low as 17.5% [3,8,9]. Because treat-
ment modalities have varied widely, including surgical
resection, radiation, and chemotherapy, optimal treat-
ment of primary adrenal DLBCL lacks consensus. The
patients with primary adrenal DLBCL had been treated
with CHOP (cyclophosphamide, doxorubicin, vincristine
and prednisone) like chemotherapy before rituximab era
and central nerve system (CNS) relapse was frequent [10].
At present, it is unclear whether R (rituximab)-CHOP
truly improve the treatment outcomes in these patients,
although a few reports show that major improvement is
possible [5,11]. Consequently, further studies with a larger
number of patients are warranted.
The purpose of this retrospective, multicenter study was
to evaluate the clinical characteristics and treatment out-
comes of the patients with primary adrenal DLBCL, focus-
ing on parameters predictive of survival in the patients
with primary adrenal DLBCL who treated with R-CHOP.
Results
Baseline characteristics
Of our initial cohort, DLBCL was histologically con-
firmed in 86.7% (39/45), while one diagnosis of Burkitt’s
lymphoma was rendered, and five other patients had T
cell lymphomas such as anaplastic large cell lymphoma,
peripheral T-cell lymphoma, not otherwise specified and
extranodal NK/T cell lymphoma, nasal type. Because of
the poor PS, 12.8% (5/39) of patients with DLBCL did not
received chemotherapy. Another 7.6% (3/39) of patients
were treated with a CHOP regimen, prior to the advent
of rituximab. Ultimately, 79.4% (31/39) of patients with
primary adrenal DLBCL (who received R-CHOP) were
eligible for analysis. Among them, 93.7% (15/16) were non-
GCB type by immunohistochemistry, and the median
value of Ki-67 expression was 80% (range, 50%-98%) from
the 19 tested patients.
The median age of patients was 64 years (range, 36–
78 years), with the male to female ratio of 2.8:1. Magni-
tudes of adrenal masses ranged from 2.0-29.8 cm (8.4 cm,
median). Sixteen patients (51.6%) presented with abdom-
inal pain, 10 patients (32.2%) complained of weight loss,
and 3 patients (7.7%) were diagnosed incidentally. B symp-
toms were observed in 15 patients (51.7%). At presen-
tation, 19 patients (61.3%) had bilateral adrenal disease, 10
patients (32.2%) fulfilled criteria for bulky disease, and
Eastern Cooperative Oncology Group (ECOG) perform-
ance status (PS) was poor (ECOG PS ≥2) in 4 patients
(12.9%). Adrenal insufficiency was confirmed in 37.5%
(6/16) of patients who were tested, and elevated serum
lactic dehydrogenase (LDH) was found in 87.1% (27/31).Twenty-four patients (77.4%) had the number of extra-
nodal involvement sites more than one. There was no
bone marrow or CNS involvement of lymphoma at the
time of diagnosis. Patients characteristics were described
in Table 1.
Treatment and outcomes
Seven patients (22.6%) received adrenalectomy for diag-
nostic and therapeutic purposes, prior to R-CHOP
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survival benefit (P= 0.979). The 31 primary adrenal
DLBCL patients received median 6 cycles of R-CHOP
chemotherapy (range, 1–8 cycles). Treatment response
evaluated in 90.3% (28/31) of these patients showed
complete remission (CR) in 54.8% (17/31) and partial re-
mission (PR) in 32.3% (10/31). One patient (3.2%) de-
veloped progressive disease (PD). Of the 10 patients
attaining PR with R-CHOP, 6 patients received add-
itional therapy. Two patients achieved CR—one after ad-
renal irradiation; the other following autologous stem
cell transplantation (ASCT) and radiotherapy—while 1
patient died due to treatment related mortality (TRM).
Three patients developed disease progression despite sal-
vage chemotherapy. The remaining 4 patients were lost
to follow-up. Flow of treatment is shown in Figure 1.
Median OS and PFS were not reached during a median
follow-up duration of 18 months (range, 1–93 months).
The 2-year estimates of OS and PFS were 68.3% and
51.1%, respectively (Figure 2A and B). Eight patients died
in the follow-up period—one patient (3.2%) from TRM
(pneumonia) during R-CHOP chemotherapy, 3 (9.6%)
from PD, and 4 (12.9%) due to TRM (3 pneumonia, 1
Steven-Johnson Syndrome) during salvage chemother-
apy. Significantly longer OS (P= 0.029, Figure 2C) and
PFS (P= 0.005, Figure 2D) were observed in the patients
achieved CR after R-CHOP chemotherapy compared to
the patients who failed to achieve CR.
Failure patterns of treatment
Among the 19 patients who achieved CR (17 after R-
CHOP and 2 after R-CHOP followed by radiotherapy or
ASCT), 4 patients (21.0%) suffered CNS (n = 2) or nodal
(n = 2) relapse. Of all patients who relapsed, 2 TRMFigure 1 Management flow chart according to the modified stage; CR
disease; NE, not evaluable; RT, radiotherapy; ASCT, autologous stemoccurred during salvage chemotherapy. Successive CR
was never observed in the patients treated with salvage
therapy. Three of the initial 10 patients achieving PR
showed disease progression after salvage chemotherapy,
involving either CNS (n = 2) or adrenal gland (n = 1).
None of the 4 patients with CNS relapse or progression
had received intrathecal prophylaxis.
Analysis of prognostic factors
By conventional Ann Arbor staging system, only 5 pa-
tients (16.1%) classified as early stage (stage IE or IIE),
while the majority (26 patients, 83.9%) belonged to
advanced stage (stage IIIE or IV). There was no survival
difference between the patients with early stage and
advanced stage (P= 0.445). None of the International
Prognostic Index (IPI) criteria (age >60 years, P= 0.232;
elevated LDH, P= 0.738; poor PS, P= 0.593; the number
of extranodal involvement sites more than one, P= 0.979)
impacted OS. According to IPI, 1 patient (3.2%) was con-
sidered low risk, 7 (22.6%) were low-intermediate, 11
(35.5%) were high-intermediate, and 12 (38.7%) were
high risk. Altogether, 23 patients (74.2%) classified as
high-intermediate or high risk patients. However, IPI
stratification failed to equate with a OS difference (P=
0.142), as did Ki-67 expression >80% (P= 0.052), bulky
disease (P= 0.647), presence of B symptoms (P= 0.841),
and presence of adrenal insufficiency (P= 0.387).
As a consequence, we elected to modify primary ad-
renal DLBCL staging system as follows: 1) stage I was
defined as the disease confined to the adrenal gland
only, regardless of unilateral or bilateral involvement, 2)
stage II included local or distant nodal disease of the ab-
domen, and 3) stage IV was indicative of disseminated
extranodal disease or concomitant supra-diaphragmatic, complete remission; PR, partial remission; PD, progressive
cell transplantation.
Figure 2 Kaplan-Meier survival analysis of primary adrenal DLBCL treated with R-CHOP. Overall survival (A) and progression-free survival
(B) of 31 patients with primary adrenal DLBCL. Overall survival (C) and progression-free survival (D) according to the response of R-CHOP.
Kim et al. Journal of Hematology & Oncology 2012, 5:49 Page 4 of 9
http://www.jhoonline.org/content/5/1/49nodal involvement. With this modified staging system,
10 patients (32.3%) were stage I, 9 (29.0%) were stage II,
and 12 (38.7%) were stage IV. Compared with advanced
stage (stage IV), early stage (stage I or II) was signifi-
cantly associated with better OS (P= 0.021, Figure 3A)
and PFS (P <0.001, Figure 3B). Survival rates, however,
were similar between stage I and stage II disease. Be-
cause bilateral involvement of adrenal gland did not sig-
nificantly impact OS (P= 0.524) and PFS (P= 0.450),
bilateral adrenal involvement was regarded as a single
involvement of extranodal site in this modified staging
system. The modified number of extranodal sites morethan one thus corresponded with poor OS (P= 0.008)
and PFS (P= 0.007). In multivariate analysis, our modi-
fied staging system showed significant survival difference
for OS (P= 0.036, HR 4.73, 95% CI 1.10-20.4) and PFS
(P= 0.003, HR 6.57, 95% CI 1.91-22.7).
IPI stratification was also revised as follows: 8 patients
(25.8%) were low risk, 13 (41.9%) were low-intermediate,
6 (19.4%) were high-intermediate, and 4 (12.9%) were
high risk. A total of 10 patients (32.2%) patients were
subsequently assigned to high-intermediate or high risk
according to the modified IPI. When these 4 risk cat-
egories were further grouped for survival comparison
Figure 3 Overall surival (A) and progression-free survival (B) according to the modified stage in primary adrenal DLBCL.
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risk patients), OS showed a significant difference (P=
0.024, Figure 4A). There was only a trend of difference in
PFS according to the modified IPI (P= 0.078, Figure 4B).
Discussion
Compared with nodal DLBCL, this study has shown that
primary adrenal DLBCL frequently accompanied by many
adverse features such as bulky disease, elevated LDH, andFigure 4 Overall surival (A) and progression-free survival (B) accordinadvanced stage. Nevertheless, we have determined that
therapeutic outcomes with R-CHOP are much better
than previously reported [3,6,8]. Of particular import, OS
of the patients with primary adrenal DLBCL is not af-
fected by bilateral involvement of adrenal gland, Ann
Arbor staging system and IPI score. Therefore, we im-
plemented a modified staging system, similar to Lugano
staging system for gastrointestinal (GI) lymphoma. With
our approach, bilateral involvement of adrenal gland wasg to the modified IPI score using modified staging system.
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ling more accurate prediction of survival (OS and PFS) in
primary adrenal DLBCL.
The definition of primary extranodal NHL is a still
controversial [12]. We defined that primary adrenal
DLBCL be confirmed histologically and dominant ad-
renal gland mass regardless of regional lymph node in-
volvement. And we also included the patients with both
dominant adrenal gland mass and other extranodal in-
volvement or concomitant supra-diaphragmatic nodal
involvement in this study because the patients with
DLBCL usually associated with aggressive clinical fea-
tures [13]. In doing so, the size of adrenal mass was
required to exceed 5 cm (reflecting TNM staging system
of adrenal gland cancer) to exclude the DLBCL from
other extranodal origin [14].
As with previous reports, the most common patho-
logic subtype of primary adrenal NHL was DLBCL
(86.7%) and most (93.7%) were non-GCB phenotype in
this study.
Optimal treatment of primary adrenal DLBCL is cur-
rently open to debate. In earlier trials of CHOP or
CHOP-like therapy, OS of 20%-50% has been reported
[6]. Our data revealed a CR rate of 54.8% and PR rate
was 32.3% after R-CHOP therapy, with 2-year estimates
of OS and PFS at 68.3% and 51.1%, respectively. Accord-
ing to the previous reports, advanced age, larger size of
tumor, presence of adrenal insufficiency, bilateral in-
volvement of adrenal gland, and elevated LDH were
related with poor prognosis in primary adrenal NHL
[7,15,16]. Most patients with primary adrenal DLBCL
accompanied by a number of these adverse features.
Most were elderly with bulky disease and/or elevated
LDH. A non-GCB phenotype also predominated, as well
as advanced stage. Nevertheless, our treatment outcomes
with R-CHOP for primary adrenal DLBCL were not in-
ferior to those of nodal DLBCL [17,18]. R-CHOP com-
bination chemotherapy may thus be a reasonable first-
line choice for treatment of primary adrenal DLBCL. It
could overcome the effect of adrenal insufficiency. With
CR after R-CHOP, OS and PFS were clearly prolonged
in our analysis. Using modified staging system, however,
only 33.3% (4/12) of patients with advanced stage pri-
mary adrenal DLBCL achieved CR after R-CHOP (Fig-
ure 1). Therefore, more aggressive treatment (ie, ASCT
consolidation after R-CHOP) should be considered in
the patients with advanced stage of primary adrenal
DLBCL according to the modified staging system.
While a majority of patients (74.2%) were initially
assigned high-intermediate or high risk IPI in this study,
conventional IPI may not be valid in primary adrenal
DLBCL for prognostic purposes. Most patients are >60
years old (61.3%) and have advanced disease (83.9%),
with elevated LDH (87.1%) and multiple (2 or more)extranodal involvement (77.4%). In our analysis, bilateral
adrenal involvement does not constitute advanced (stage
IV) disease, because there was no OS difference between
bilateral and unilateral adrenal gland involvement (P=
0.524). Furthermore, we found that with modification of
the number of extranodal involvement (bilateral involve-
ment of adrenal gland was considered as a single-site
extranodal involvement), OS (P= 0.008) and PFS (P=
0.007) actually differ significantly for advanced vs. early
stage of primary adrenal DLBCL. Accrual of involved
extranodal sites for paired organs in Ann Arbor staging
system still remains controversial. Bilateral involvement
of primary breast DLBCL was classified as stage IV [19],
while primary lymphoma of both testes classified as
stage I [13]. Consequently, bilateral primary adrenal
DLBCL also might be reasonable to be classified as stage
I and single involvement of extranodal site.
Ann Arbor staging system has already been shown un-
suitable for some types of extranodal NHL, namely GI
lymphoma. In our study, survival differences according
to the conventional Ann Arbor staging system went un-
detected, because most patients (77.4%) were stage IV
by Ann Arbor staging system. We therefore instituted
modifications similar to the Lugano staging system for
GI lymphoma [20], defining 3 stages of primary adrenal
DLBCL by extent of disease and nodal dissemination.
Theoretically, there was no stage III disease in our new
definition. With this proviso, early stage (stage I or II)
disease fared significantly better in terms of OS and PFS,
compared with advanced stage (stage IV) disease. Even
with modified staging system, survival was comparable
for stage I and II localized disease. On the other hand,
modified IPI stratification resulted in a significant dif-
ference in OS for low or low-intermediate vs. high-
intermediate or high risk IPI groups, while PFS did not
differ. Because conventional IPI criteria yielded no sur-
vival differences, new modified IPI should be considered
for evaluating the prognosis of primary adrenal DLBCL.
Recent study reported that the risk of CNS relapse
was high in primary adrenal NHL [6,10]. While the inci-
dence of CNS disease at diagnosis is likely lower than
general estimates, our data showed CNS relapse in four
patients (12.9%), while two suffered CNS relapse after R-
CHOP therapy, and another two relapsed in CNS after
salvage chemotherapy. The rate of CNS recurrence in
aggressive NHL (without CNS prophylaxis) is on the
order of 2.2%-5% [21-23]. Hence, CNS prophylaxis might
be considered in primary adrenal DLBCL like other
extranodal NHL such as primary testicular lymphoma.
Limitations of this study include its small patient pop-
ulation and retrospective nature. Unfortunately, a pro-
spective, randomized trial would be difficult to conduct,
given the exceptionally low disease incidence. Although
another published case series (n = 15) of primary adrenal
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analysis is the largest known study of primary adrenal
DLBCL thus far.
Conclusions
Our findings suggest that R-CHOP combination chemo-
therapy is an effective first-line regimen for primary ad-
renal DLBCL, despite the inherently poor prognosis of
this disease. Furthermore, our staging modifications,
which redefine extranodal involvement, more accurately
reflect treatment outcomes and may be preferential in
this setting.
Patients and methods
Patient population
From 14 Korean institutions, a total of 45 patients with
primary adrenal NHL, newly diagnosed between January,
1998 and December, 2011, were retrospectively reviewed.
Thirty nine (86.7%) patients were diagnosed as primary
adrenal DLBCL. Among them, 31 patients were treated
with R-CHOP and reviewed in this study. Primary ad-
renal DLBCL was defined as follows: (1) histologic con-
firmation as DLBCL, with dominant adrenal gland mass
regardless of regional lymph node involvement, and (2)
absence of leukemic manifestations [24]. Patients with
disease of other extranodal sites or lymph nodes above
diaphragm were included in this analysis, provided their
largest extranodal mass was adrenal-based and reached
a relatively large size (> 5 cm) [25]. In DLBCL patients,
molecular classification as GCB or non-GCB relied on
Hans criteria [26]. The percentage of tumor cells with
Ki-67 nuclear antigen expression was evaluated in im-
munophenotypic studies. Patient characteristics, as
documented in medical records, were retrospectively ex-
amined to identify potential prognostic variables. These
variables included age, gender, ECOG PS, initial present-
ing symptoms, presence of B symptoms, magnitude of
adrenal gland mass, presence of adrenal insufficiency,
pertinent laboratory determinants (ie, electrolytes, serum
LDH), and related treatment data. Bulky disease was
defined as a adrenal gland mass with the largest dimen-
sion greater than 10 cm. Adrenal insufficiency, when
clinically suspected, was diagnosed via cortisol level or
rapid ACTH stimulation test. None of the patients had
taken immunosuppressive agents. This study was ap-
proved by the Institutional Review Board of each partici-
pating institution.
Stage and prognostic index
All patients were staged in accordance with the Ann
Arbor staging system [27], classifying unilateral primary
adrenal DLBCL as stage IE and bilateral primary adrenal
DLBCL as stage IV. Using IPI criteria (age >60 years,
stage III/IV disease, elevated LDH level, ECOG PS ≥2,and more than one extranodal site of disease) [28],
each patient was stratified to one of four risk groups by
IPI: 0 to 1, low risk; 2, low-intermediate risk; 3, high-
intermediate risk; and 4 to 5, high risk.Treatment and response
Treatment outcomes were analyzed in primary adrenal
DLBCL patients who treated with R-CHOP. The R-CHOP
regimen was administered by intravenous (IV) or oral
(PO) route in 21-day cycles: rituximab (375 mg/m2, IV),
cyclophosphamide (750 mg/m2, IV), doxorubicin (50
mg/m2, IV), vincristine (1.4 mg/m2, IV) on Day 1 and
prednisone (100 mg, PO) on Days 1–5. Cerebrospinal
fluid was examined only if clinically indicated. Response
was assessed after completion of the R-CHOP chemo-
therapy, using International Working Group criteria [29].Statistical analysis
OS was measured from the first date of diagnosis until
death from any cause, with surviving patients were cen-
sored at the last follow up date. PFS was defined from
the first date of diagnosis until disease progression, re-
lapse after response or death due to lymphoma or treat-
ment related. Other causes of death or surviving patients
at last follow up were censored. Survival curves were
plotted by the Kaplan-Meier method and compared
using the log-rank test. The influence of each prognostic
factors identified by univariate analysis was assessed by
multivariate analysis using Cox’s proportional-hazards
regression by stepwise method. P-value <0.05 was con-
sidered statistically significant in all analyses. All sta-
tistical analyses were performed using the SPSS for
Windows, Version 18.0.
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